

# Connectome-based modeling of real world clinical outcomes

Sarah W. Yip, DPhil, MSc



Assistant Professor of Psychiatry and of Child Study

Director, Yale Imaging & Psychopharmacology (YIP) Lab


# Clinical reality

- Excellent evidence-based treatments exist
- Same tx highly variable across individuals
- High relapse rates + multiple failed attempts
  - retention in opioid tx <6 months for 30-50%
  - increased overdose risk following treatment
- ‘Traditional’ variables do not predict outcomes
  - e.g., little variance explained by baseline cocaine use


# Neuroimaging of addiction outcomes



Yip et al., Drug Alcohol Depend, 2014



Balodis et al, Neuropsychopharmacol, 2016



Gu et al., Brain, 2014

# Limitations


- Small sample sizes; e.g.,  $n=25$ 
  - reflection of complexity of translational research
- Use of methods that may overfit the data
  - inflated effect sizes
  - decreased likelihood of generalization
- Prior studies activation-based or ROI-based
  - network based approaches may be more informative
  - data-driven approaches can provide novel insight

# Machine learning (aka predictive modeling)

- Training dataset > predictive model
- Test dataset > model validation
- Goal = generate predictions in novel data
- Key step for translation into clinical setting
- Can also be used for neurobiological discovery

# Part I: Prediction of cocaine abstinence

# Study design



\*opioid-dependent, methadone-maintained

#behavioral therapy +/- galantamine to treat cocaine-use

Yip et al., *American Journal of Psychiatry*, 2019

# **Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence:**

A Randomized Clinical Trial

**Kathleen M. Carroll, PhD<sup>a,\*</sup>; Charla Nich, MS<sup>a</sup>; Elise E. DeVito, PhD<sup>a</sup>; Julia M. Shi, MD<sup>a,b</sup>; and Mehmet Sofuoglu, MD, PhD<sup>a,c</sup>**

- > 64% male
- > 73% unemployed
- > cocaine primarily smoked (70%)
  
- > + 3 prior outpatient treatment attempts
- > + 3 prior inpatient treatments attempts
- > + 5 lifetime arrests

Yip et al., *American Journal of Psychiatry*, 2019


# Using connectome-based predictive modeling to predict individual behavior from brain connectivity

Xilin Shen<sup>1</sup>, Emily S Finn<sup>2</sup>, Dustin Scheinost<sup>1</sup>, Monica D Rosenberg<sup>3</sup>, Marvin M Chun<sup>2-4</sup>, Xenophon Papademetris<sup>1,5</sup> & R Todd Constable<sup>1,2,6</sup>

506 | VOL.12 NO.3 | 2017 | **NATURE PROTOCOLS**


- > data-driven machine learning approach
- > no a priori specification of networks
- > predict and identify networks
- > input = task-based connectivity matrices

# Brain state manipulation improves prediction




Greene et al., *Nature Communications*, 2018

# Monetary incentive delay task




Andrews et al., *Biological Psychiatry*, 2011


# A. Feature selection from FC matrices (training data)




# B. Sum edge weights




# C. Fit brain-behavior model



# D. Apply model to novel data




# Model validation - predictive accuracy



\*not associated w/  
baseline cocaine-use

Yip et al., *American Journal of Psychiatry*, 2019

# Abstinence networks\*




\*only 539 connections <2% of possible connections

# Short versus long-range connectivity




$$\sqrt{((x_0-x_1)^2+(y_0-y_1)^2+(z_0-z_1)^2)}$$



- Positive network (+ abstinence) > longer range
- Negative network (- abstinence) > shorter range











# Regional connectivity




Yip et al., *American Journal of Psychiatry*, 2019

# 'Canonical' networks



## Networks

-  1 Medial frontal
-  2 Frontoparietal
-  3 Default mode
-  4 Sensori-motor
-  5 Visual a
-  6 Visual b
-  7 Visual asso
-  8 Salience
-  9 Subcortical
-  10 Cerebellum/  
brain stem




Horien et al., *NeuroImage*, 2019

# Network connectivity




Yip et al., *American Journal of Psychiatry*, 2019





# Post-treatment networks predict abstinence\*

Post-treatment fMRI (n=40)



+




\*no changes in connectivity over time

Yip et al., *American Journal of Psychiatry*, 2019

But does it replicate?

# Replicates in heterogeneous, independent sample




Yip et al., *American Journal of Psychiatry*, 2019

## Part II: Networks across drugs and brain states



Sarah Lichenstein, PhD

# Same study, different drug



\*opioid-dependent, methadone-maintained


#behavioral therapy +/- galantamine to treat cocaine-use

# Different mood states predict opioids vs. cocaine

**Results:** During the 5 hours preceding cocaine use or heroin craving, most of the 12 putative triggers showed linear increases. Cocaine use was most robustly associated with increases in participants reporting that they “saw [the] drug” ( $P < .001$ ), were “tempted to use out of the blue” ( $P < .001$ ), “wanted to see what would happen if I used” ( $P < .001$ ), and were in a good mood ( $P < .001$ ). Heroin craving was most robustly associated with increases in reports of feeling sad ( $P < .001$ ) or angry ( $P = .01$ ). Cocaine craving and heroin use showed few reliable associations with any of the putative triggers assessed.


Epstein et al., *Archives of General Psychiatry*, 2009

# Cognitive control (Stroop) task




- engages fronto-parietal and cortico-striatal regions

# Opioid model - predictive accuracy



# Opioid network











<3% of possible connections

# Shared edges across opioid and cocaine networks

Consistent edges

<1% overlap

Opposing edges



cocaine+  
opioid+


cocaine-  
opioid-

cocaine+  
opioid-


cocaine-  
opioid+

# Opioid network connectivity


Positive network



Negative network




Positive - Negative



Lichenstein et al., *Molecular Psychiatry*, In Press


# Theoretical opioid network model



Lichenstein et al., *Molecular Psychiatry*, In Press

Are networks drug or brain state specific?

# Network identification is brain-state dependent



Lichenstein et al., *Molecular Psychiatry*, In Press

# Cocaine network across drugs and brain states




Opioid use




Cocaine use


Reward task



Cognitive task



Resting state



$$\rho_{(df=52)}=0.11, p=.425$$

$$\rho_{(df=52)}=0.70, p<.001$$

$$\rho_{(df=35)}=0.41, p=.014$$

*Cocaine network does not predict opioid use*

*...but does generalize across tasks.*

# Opioid network across drugs and brain states




Opioid use



Cocaine use


Cognitive task



cocaine use

$$\rho_{(df=52)}=0.07, p=.606$$


Reward task



opioid use

$$\rho_{(df=52)}=0.71, p<.001$$

Resting state



opioid use

$$\rho_{(df=35)}=0.46, p=.005$$

*Opioid network does not predict cocaine use*

*...but does generalize across tasks.*



# Network across drugs and brain states

	Cocaine Network		Opioid Network	
	Cocaine	Opioid	Opioid	Cocaine
Reward	✓	x	✓	x
Cognitive	✓	x	✓	x
Resting	✓	x	✓	x

Lichenstein et al., *Molecular Psychiatry*, In Press

# Post-treatment connectivity predicts opioid use\*

Post-treatment fMRI (n=40)




\*no changes in opioid connectivity over time

# Pathology versus prediction

- Pathophysiology may not predict abstinence
  - what changes w/ abstinence  $\neq$  predict abstinence
- Initial and sustained responses may have different basis
  - motivation to change  $>$  early tx response
  - acquisition of new skills  $>$  sustained tx response
- Protracted neural change?
  - abstinence rates improve post-treatment
    - e.g., Carroll et al., *Addiction*, 2000


# Prediction versus pathology?

# Theoretical model



Garavan et al., *Current Opinion in Neurobiology*, 2013

# Theoretical model



*adapted from Garavan et al., Current Opinion in Neurobiology, 2013*

# Healthy controls

**n=38 controls participants**

No substance-use disorders

Drawn from ongoing Yale  
Psychiatry research protocols

38 years old (SD=9.06)

58% male

**n=53 patients**

Cocaine + opioid use disorders

Recruited from RCT for CUD +  
methadone treatment for OUD


35 years old (SD=9.37)

74% male

identical acquisition, tasks & connectivity pipeline


Lichenstein et al., *Molecular Psychiatry*, In Press

# Cocaine network




Lichenstein et al., *Molecular Psychiatry*, In Press

# Opioid network




Lichenstein et al., *Molecular Psychiatry*, In Press

# Protracted neural change?



# Second external replication



# Part III: Considerations for clinical prediction

# Clinical workflow

## 1. Define Question

identify clinical population  
define treatment response

## 2. Select timing of fMRI

pre-tx, early in tx, post-tx?  
define window of assessment

## 3. Collect baseline data

acquire neuroimaging data  
acquire baseline clinical data

## 4. Collect longitudinal data

measure substance use over time  
collect treatment-related measures

## 5. Select algorithm


is outcome categorical or continuous?  
ROI/NOI- or data-driven approach?

## 6. Separate data and run predictive model

### Cross-validation

a. Split data into train and test

Example fold of LOOCV:



b. Fit model with training data

c. Predict testing data

d. Repeat steps a-c

e. Optional: nested CV

f. Optional: external validation

## 7. Evaluate model

compare actual and predicted values  
quantify statistically using permutation  
testing (required for CV)

## 8. Understand results

check for effects of other variables  
post-hoc testing (e.g., virtual lesioning)  
update theoretical framework

## 9. Improve clinical care

develop/improve tx based on findings  
conduct additional research to refine  
predictive model

Yip et al., *Biological Psychiatry: CNNI*, 2020

# 'Best' metric depends on the question

Outcome 1. Assignment to active treatment

High sensitivity / low specificity		Low sensitivity / high specificity	
TP	FP	TP	FP
n=70	n=20	n=5	n=5
<b>FN</b>	TN	<b>FN</b>	TN
<b>n=5</b>	n=5	<b>n=70</b>	n=20

Outcome 2. Termination of active treatment

High sensitivity / low specificity		Low sensitivity / high specificity	
TP	<b>FP</b>	TP	<b>FP</b>
n=70	<b>n=20</b>	n=5	<b>n=5</b>
FN	TN	FN	TN
n=5	n=5	n=70	n=20

Yip et al., *Biological Psychiatry: CNNI*, 2020

# Clinical workflow

## 1. Define Question

identify clinical population  
define treatment response

## 2. Select timing of fMRI

pre-tx, early in tx, post-tx?  
define window of assessment

## 3. Collect baseline data

acquire neuroimaging data  
acquire baseline clinical data

## 4. Collect longitudinal data

measure substance use over time  
collect treatment-related measures

## 5. Select algorithm


is outcome categorical or continuous?  
ROI/NOI- or data-driven approach?

## 6. Separate data and run predictive model

### Cross-validation

a. Split data into train and test

Example fold of LOOCV:



b. Fit model with training data  
c. Predict testing data  
d. Repeat steps a-c

e. Optional: nested CV  
f. Optional: external validation

## 7. Evaluate model

compare actual and predicted values  
quantify statistically using permutation  
testing (required for CV)

## 8. Understand results

check for effects of other variables  
post-hoc testing (e.g., virtual lesioning)  
update theoretical framework


## 9. Improve clinical care

develop/improve tx based on findings  
conduct additional research to refine  
predictive model


Yip et al., *Biological Psychiatry: CNNI*, 2020

# Elucidation as a goal of prediction


Connection (or edge) level




Region (or node) level



Network / systems level




Theory / mechanism level



Levels of interpretation

Yip et al., *Biological Psychiatry: CNNI*, 2020


# Elucidation as a goal of prediction



Yip et al., *Biological Psychiatry: CNNI*, 2020

# Thank you!

Key collaborators: Sarah Lichenstein, PhD, Dustin Scheinost, PhD, Brian Kiluk, PhD, Marc Potenza, MD, PhD, Kathleen Carroll, PhD



## Yale Imaging & Psychopharmacology

K01 DA039299 (Yip), P50 DA009241 (Carroll), R21 DA045969 (Yip),  
R21 DA049583 (Garrison/Scheinost/Yip), R01 AAA027553 (Yip/  
Scheinost), NARSAD Young Investigator Award (Yip)